Flamingo Therapeutics appoints new board member and more digital health hires
22 Mar 2024
Executive Change
Preview
Source: mobihealthnews
Photo: Shannon Fagan/Getty Images
RNA-focused digital therapeutics company Flamingo Therapeutics added a new member to its board of directors, Dr. Ezra Cohen.
Dr. Cohen has a history in the development of pharmaceuticals, especially head and neck cancers.
"The science and team at Flamingo are very impressive, and I am excited to join the board following the recent initiation of several important oncology clinical studies. I believe that Flamingo is uniquely positioned to improve the head and neck treatment landscape with its RNA-targeting approach, and I look forward to working with the team to deliver new therapeutic options for patients," Dr. Cohen said in a statement.
Life sciences software company Synthace announced the appointment of Willem Baralt as its new chairman of the board. Baralt joined the company in February.
Synthace supports R&D scientists through automation across various stages, including experimental design, simulations and the creation of comprehensive digital records.
Baralt has served on several boards of healthcare and charitable organizations. Most recently, he served at portable dialysis machine maker Quanta Dialysis Technologies, which secured $245 million in Series D funding in 2021.
"I am truly honored to join the Synthace team at this point in time as it is looking to transform the life sciences R&D landscape. With its digital experimentation platform, Synthace empowers scientists to design and execute experiments that were previously impossible. Synthace's technology is key to enabling the R&D lab of the future, allowing its customers to make new therapies while achieving radical time and cost savings," Mr. Baralt said in a statement.
Tags: Synthace, flamingo therapeutics, digital therapeutics, RNA, digital health hires, hires
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.